Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn's disease: Post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 studies
J Crohns Colitis 2024;18:818–27 doi: 10.1093/ecco-jcc/jjad206
This post hoc analysis provides additional support for the utility of risankizumab therapy in patients with moderately to severely active CD. Investigators examined the efficacy of risankizumab for providing early symptom relief, along with the prognostic value of early symptom relief for achieving future clinical and endoscopic endpoints.
No new safety signals with risankizumab were observed in the ADVANCE or MOTIVATE studies, and the overall safety profile was consistent with the known safety profile of RZB
Keywords:
